<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">In a large population-based case–control study, the impact of RAAS blockers use on COVID-19 severity was assessed in 6,272 patients who tested positive for SARS-CoV-2 infection; the use of ACEi/ARBs was not associated with an increased COVID-19 risk or a worse prognosis [
 <xref ref-type="bibr" rid="CR30">30</xref>]. Likewise, in a retrospective study with 12,594 individuals evaluating the relation between previous hypertension treatment with ACEi, ARBs, β-blockers, calcium-channel blockers, or thiazide diuretics and increased severe illness and contamination risk, no substantial association between the use of these drugs and more severe SARS-CoV-2 infection was demonstrated [
 <xref ref-type="bibr" rid="CR33">33</xref>].
</p>
